A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01766336
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
296
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
Group 1 ELND005
DRUG:
Group 2 ELND005
Sponsor
OPKO Health, Inc.
Collaborators
[object Object]